Reye syndrome warning
This article was originally published in The Tan Sheet
Executive Summary
Aspirin Foundation of America urges FDA in a July 6 letter to "not propose similar modifications to the aspirin label warning for Reye syndrome as are being proposed for bismuth subsalicylate." The foundation argued that there are fundamental differences between bismuth subsalicylate and aspirin that would not accommodate the same label warning. P&G also recently told FDA that a link between Reye syndrome and non- aspirin salicylates has not been established ("The Tan Sheet" July 12, p. 12)